cas 441797-42-8|| where to buy N-[5-(4-Bromophenyl)-6-chloro-4-pyrimidinyl]-N'-(phenylmethyl)sulfamide

Nombre del producto:N-[5-(4-Bromophenyl)-6-chloro-4-pyrimidinyl]-N'-(phenylmethyl)sulfamide

IUPAC Name:benzyl({[5-(4-bromophenyl)-6-chloropyrimidin-4-yl]sulfamoyl})amine

: CAS：441797-42-8; Fórmula molecular：C17H14BrClN4O2S; Pureza：95%+

Unidad de embalaje	Stock disponible	Precio($)
CM337693-100mg	in stock	ĽĽȎ
CM337693-250mg	in stock	ȎȎŢ
CM337693-1g	in stock	ƄƄȀ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 441797-42-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :441797-42-8; Fórmula molecular:C17H14BrClN4O2S; Punto de fusión:-; Código de sonrisas:O=S(NCC1=CC=CC=C1)(NC2=NC=NC(Cl)=C2C3=CC=C(Br)C=C3)=O; Densidad:

: Número de catálogo:CM337693; Peso molecular:453.74; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Aprocitentan; New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023.
Aprocitentan is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
A new drug application (NDA) for aprocitentan was accepted for review by the US FDA.